Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy

NCT01961349 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01961349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01961349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
March 31, 2014
Enrollment
279 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

sedation to be moderate for a diagnostic gastrointestinal endoscopy and gastrointestinal endoscopic polypectomy